Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

You must have been troubled by when to say "I love you" because it is one of the greatest puzzles in our life. What if you say it first and your partner doesn't love you back? Or if they do say it but you don't feel they mean it? Being the first to declare your love can be never racking and risky and can leave you feeling as vulnerable as a turtle with no shell. But is the person who says it first really in a position of weakness? Doesn't it pay to hold back, play it cool and wait until the other half has shown their hand faster? "A really good relationship should be about being fair and being equal," says psychologist Sidney Crown. "But love is seldom equal." "All relationships go through power struggles but," he says, "if a love imbalance continues for years, the rot will set in." That feeling of "I've always loved you more" may be subverted (,) for a time, but it never goes away completely and it often emerges in squabbling . In love, at least, the silent, withholding type is not always the most powerful. "The strongest one in a relationship is often the person who feels confident enough to talk about their feelings," says educational psychologist Ingrid Collins. Psychosexual therapist Paula Hall agrees. "The one with the upper hand is often the person who takes the initiative." In fact, the person who says "I love you" first may also be the one who says "I'm bored with you' first." Hall believes that much depends on how "I love you" is said and the motivation of the person saying it. Is it said when they're drunk? Is it said before their partner flies off on holiday, and what it really means is "Please don' t be unfaithful to me" ? By saying "I love you", they are really saying "Do you love me?" If so, wouldn't it just be more honest to say that. Collins agrees that intention is everything. "It's not what is said, but how it's said. What it comes down to is the sincerity of the speaker."
What is the most important for you to consider when somebody say "I love you" to you?

The SP790 study (ClinicalTrials.gov, NCT00136045) showed benefits of rotigotine over placebo in improving symptom severity of restless legs syndrome (RLS), also known as Willis-Ekbom disease, on the International Restless Legs Syndrome Study Group rating scale (IRLS), Clinical Global Impression item 1 (CGI-1), RLS 6-item questionnaire (RLS-6), and the RLS-quality of life questionnaire (RLS-QoL) in patients with moderate to severe idiopathic RLS. To provide clinical context for the IRLS and to guide the choice of assessment scales for RLS studies, our post hoc analysis of SP790 data evaluated associations between the IRLS and the CGI-1, IRLS and RLS-6, and the IRLS and RLS-QoL. Scale associations were analyzed at baseline and at the end of maintenance (EoM) using data from the safety set (rotigotine and placebo groups combined [n=458]). Changes from baseline to EoM in IRLS score vs comparator scale scores also were analyzed. There was a trend towards increasing IRLS severity category with increasing CGI-1, RLS-6, and RLS-QoL score. Pearson product moment correlation coefficients showed correlations between IRLS and comparator scale scores at baseline and EoM as well as correlations for change from baseline to EoM. Correlations between the IRLS and comparator scales were substantial. These data indicate that the IRLS is clinically meaningful. The IRLS and CGI-1 are generally sufficient to evaluate the overall severity and impact of RLS symptoms in clinical trials.
Willis-Ekbom disease is also known as?

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.

Which human disease is associated with mutated UBQLN2

